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Abstract: Armodafinil is the pharmacologically active R-enantiomer of modafinil, a widely 
prescribed wake-promoting agent used to treat several sleep-related disorders including exces-
sive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive 
sleep apnea/hypopnea syndrome. Remarkably, however, the neuronal circuitry through which 
modafinil exerts its wake-promoting effects remains unresolved. In the present study, we 
sought to determine if the wake-promoting effects of armodafinil are mediated, at least in part, 
by inhibiting the sleep-promoting neurons of the ventrolateral preoptic (VLPO) nucleus. To 
do so, we measured changes in waking following intraperitoneal administration of armodafinil 
(200 mg/kg) or the psychostimulant methamphetamine (1 mg/kg) in rats with cell-body specific 
lesion of the VLPO. Rats with histologically confirmed lesions of the VLPO demonstrated 
a sustained increase in wakefulness at baseline, but the increase in wakefulness following 
administration of both armodafinil and methamphetamine was similar to that of intact animals. 
These data suggest that armodafinil increases wakefulness by mechanisms that extend beyond 
inhibition of VLPO neurons.
Keywords: EEG, sleep, orexin-saporin, methamphetamine
Introduction
Modafinil is a wake-promoting agent that is currently approved by the US Food 
and Drug Administration (FDA) for the treatment of excessive daytime sleepiness 
associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea/
hypopnea syndrome.1,2 As the wake-promoting effects are due mainly to the R-isomer, 
armodafinil, this agent has now been introduced for clinical use.3 At present, however, 
little is known about armodafinil’s cellular mechanism of action for enhancing arousal.4 
Nevertheless, several studies have suggested an important role for brain dopaminergic 
and noradrenergic signaling mechanisms in mediating the wake-promoting effects 
of the racemic mixture of modafinil in vivo.5–7 More recent work has suggested the 
interesting possibility of a dopamine-dependent adrenergic signaling mechanism of 
action for modafinil, although this remains largely untested.8 Similar to its unresolved 
mode of action, the central nervous system (CNS) site(s) at which modafinil exerts 
its wake-promoting effects also remains uncertain. Given its potent wake-promoting 
properties it would be reasonable to postulate that armodafinil suppresses or facilitates, 
respectively, the activity of sleep- or wake-promoting systems.
We hypothesize that inhibition of the ventrolateral preoptic nucleus (VLPO) may be 
a mechanism for mediating the arousal-promoting effects of armodafinil. Neurons of the 
VLPO are sleep-active and cell-body specific lesions of the VLPO result in profound Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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insomnia in rats.9–11 During the waking period, sleep-active 
VLPO neurons are inhibited by inputs from brainstem mono-
aminergic arousal systems, including both dopaminergic and 
noradrenergic systems.12 Several converging lines of evidence 
suggest a possible role for the VLPO in mediating the wake-
promoting effects of armodafinil: 1) noradrenergic inhibition 
of the VLPO is potentiated by racemic mixed modafinil in 
vitro;13 2) dopamine inhibits the VLPO through activation 
of α2 adrenoreceptors;14 and 3) c-Fos labeling in the VLPO 
is reduced following modafinil treatment.15 Thus, there are 
ample data to suggest that the VLPO may be a neuroanatomic 
substrate through which armodafinil mediates its effects on 
wakefulness. We tested this hypothesis in the present study 
by evaluating the wake-promoting properties of armodafinil 
in rats with VLPO lesions.
Methods
animals
Pathogen free adult male Sprague Dawley rats (300–350 g) 
were housed in individual cages. The cages were set within 
inside sound-attenuating isolation chambers, which provided 
ventilation, lighting (12:12 light-dark cycle; light on at 7 am) 
and visual isolation. Care of the rats in the experiment met 
National Institutes of Health standards, as set forth in the 
Guide for the Care and Use of Laboratory Animals, and all 
protocols were approved by the Harvard Medical School and 
Beth Israel Deaconess Medical Center Institutional Animal 
Care and Use Committees.
Surgery
Under chloral hydrate anesthesia (7% in saline, 350 mg/kg), 
a burr hole was made in the skull and a fine glass pipette 
(1 mm glass stock, tapering slowly to a 10–20 mm tip) 
containing 0.1% orexin-saporin (OX-SAP) was lowered to 
the VLPO (coordinates AP −0.6 from bregma, ML ±1.00, 
DV −8.5 as per the atlas of Paxinos and Watson16) and 200 
nL OX-SAP was injected (VLPOx rats; n=11). Another 
set of rats (n=6) received an equivalent volume injection 
of saline into the VLPO and served as sham-lesioned con-
trols (sham-L). For the collection of sleep-wake data (ie, 
electroencephalography/electromyography [EEG/EMG] 
recordings) from these rats, four EEG screw electrodes were 
implanted into the skull, two each laterally in the frontal 
and parietal bones, and two flexible EMG wire electrodes 
were placed into the neck muscles. The free ends of the 
leads were soldered into a socket that was attached to the 
skull with dental cement, and the incision was then closed 
with wound clips.17
Sleep-wake recordings and analysis
After 2 weeks of postoperative recovery, the rats were con-
nected via flexible recording cables to a commutator, which, 
in turn, was connected to a Grass polygraph and computer. 
The rats were habituated to the cables for 1 day. Continuous 
recording of EEG/EMG began after this habituation period 
and continued for 48 hours or 72 hours, interrupted only 
by injections (armodafinil, methamphetamine, or vehicle). 
The digitized EEG/EMG data of each rat were divided into 
12 second epochs and visually scored as wake, non-rapid eye 
movement (NREM) sleep, or rapid eye movement (REM) 
sleep using established criteria.11 Scoring was done before 
histological examination; scorers were unaware of both the 
extent of the lesions and the administered drug/vehicle.
Drug administration
In this study we used armodafinil, which is the isolated 
R-isomer of modafinil and methamphetamine. Armodafinil 
was suspended in a vehicle solution (Tween; Cephalon Inc, 
Frazer, PA, USA) and administered at a dose of 200 mg/kg 
bodyweight (bw). Similarly, methamphetamine was dissolved 
in saline and administered at a dose of 1 mg/kg bw. All injec-
tions were administered at 10 am (early-subjective day) since 
this corresponds to the time of maximal sleep tendency in 
the rat’s normal rest/sleep period.
histology
Animals were sacrificed using deep anesthesia (500 mg/
kg chloral hydrate) followed by transcardial perfusion with 
50 mL saline, followed by 250 mL of neutral phosphate buff-
ered formalin (Fischer Scientific Co, Waltham, MA, USA). 
Brains were removed, incubated in 20% sucrose at 4°C, and 
then sectioned at 40 µm on a freezing microtome. To assess 
the completeness of lesions generated using orexin-saporin, 
we performed Nissl stains on one series from each brain. 
This was done by mounting the series on gelatin-coated 
slides, and washing in H2O and then phosphate buffered 
saline (PBS). Sections were then incubated in 0.25% thionin 
in 0.1 M acetate buffer solution for 2 minutes, differentiated 
in graded ethanols, and delipidated in xylene before being 
coverslipped. Lesion sites were then identified based on neu-
ronal loss and gliosis, and the lesion size was then quantified 
by counting the number of remaining neurons in the VLPO. 
The construction of counting boxes and the counting method 
were similar to those used in previous studies.10,11 Cell profile 
counts were made bilaterally on three sections (separated by 
160 µm) for the VLPO cluster, medial extended VLPO, and 
dorsal extended VLPO region, by counting only neurons with Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
59
Armodafinil and wakefulness in animals with preoptic lesions
clear nuclei. The profile counts were corrected for overcount-
ing by using the Abercrombie factor. Percentage of cell loss 
in each of these VLPO subregions was estimated using the 
following equation:
  100 − (RN × 100/MCC)  (1)
where RN represents the remaining number of neurons 
in that subregion of the VLPO in each VLPOx rat and 
MCC represents the mean cell count in the same region in 
sham-L rats.
Only animals with .70% cell loss bilaterally in the VLPO 
cluster were included in the final analysis as VLPO lesions 
of this magnitude have been shown to produce a profound 
increase in wakefulness.10,11
For c-Fos immunohistochemistry, brain sections were 
first washed in PBS and incubated in primary antiserum 
diluted in PBS containing 0.3% Triton X-100 and 0.2% 
sodium azide for 1 day at room temperature. Sections were 
then washed in PBS and incubated in biotinylated secondary 
antiserum (against appropriate species IgG, 1:1,000, Vector 
Laboratories, Burlingame, CA, USA) in PBS for 1-hour, 
washed in PBS and incubated in ABC reagents for 1-hour. 
Sections were then washed again and incubated in a solution 
of 0.06% 3,3-diaminobenzidine tetrahydrochloride (DAB; 
Sigma-Aldrich, St Louis, MI, USA), 0.02% H2O2 and 0.05% 
cobalt chloride and 0.01% nickel ammonium sulfate. The 
c-Fos antibody (1:50,000, AB5, ∼55kD; EMD Millipore, 
Billerica, MA, USA) used was a rabbit polyclonal antibody 
raised against residues 4–17 from human c-Fos, and it stained 
characteristic patterns of cells in the hypothalamus and cere-
bral cortex in both waking and sleeping intact rats.15
Data analysis
In order to assess the changes in sleep-wake following VLPO 
lesions, the percentage of time spent in wake, NREM sleep, 
and REM sleep during a 24-hour period was calculated for 
VLPOx rats and compared with those of sham-L animals using 
an unpaired t-test. To determine changes in sleep-wake follow-
ing administration of the drug/vehicle, we analyzed the first 
6 hours (divided into 1 hour bins) of post-injection data from 
the sham-L and VLPOx rats. The percentage of time spent in 
wake, NREM, and REM from the six 1 hour bins following 
armodafinil or methamphetamine administration in the VLPOx 
rats was compared with the respective bins following vehicle 
injections in the VLPOx rats using paired t-tests and with the 
respective bins following armodafinil or methamphetamine 
injections in the sham-L rats using unpaired t-tests.
Results
To test our hypothesis, we compared EEG and behavioral 
arousal responses to armodafinil (200 mg/kg; the isolated 
R-isomer of modafinil), methamphetamine (1 mg/kg) or 
vehicle injection in both sham-L and VLPOx rats. In pre-
liminary dosing experiments, we found that armodafinil at 
200 mg/kg produced near-equivalent waking (about 3 hours) 
to that of methamphetamine at 1 mg/kg and so utilized this 
dosing scheme for our experiments. At these respective 
dosages, armodafinil and methamphetamine produced a 
sustained and highly reproducible increase in waking for 
about 3 hours after the injections in sham-L rats.
Wake promoting effects of modafinil  
or methamphetamine in VlPOx rats
Consistent with our previous reports, rats with histologi-
cally verified .70% cell loss (n=11) in the VLPO dem-
onstrated significant and sustained increases in baseline 
waking (approximately 34%) and a concomitant reduc-
tion in both NREM and REM sleep (Figure 1). Following 
this analysis of baseline sleep-wake recording in VLPOx 
and Sham-L animals, we evaluated the wake-promoting 
effects of armodafinil, methamphetamine, and vehicle 
injections.
VLPOx rats displayed a significant increase in wake 
for about 3 hours following both armodafinil (paired t-test; 
t=−3.44, P,0.05; t=−8.107, P,0.001; and t=−5.229, 
P,0.01, respectively) and methamphetamine (paired 
t-test; t=−3.443, P,0.05; t=−8.107, P,0.001; and 
t=−3.051, P,0.05, respectively) administration (Figure 
2A and B) compared with vehicle injections. The percent-
ages of wake during each of the first three 1 hour bins fol-
lowing armodafinil and methamphetamine administration 
was 100% in both the intact and in the VLPOx rats. It could 
be argued that this “ceiling effect” limited our ability to 
detect differences between the two groups. Wakefulness in 
the VLPOx rats however also continued to be higher after 
this 3 hour period compared to sham-L animals, and statisti-
cal significance was observed at 5 hours after armodafinil 
(unpaired t-test; t=2.401, P,0.05) and at 5 and 6 hours after 
methamphetamine (unpaired t-test; t=4.426, P,0.01 and 
t=−2.358; P,0.05, respectively). In summary, the VLPOx 
rats showed the same level of wake as the intact rats after 
armodafinil, but because their baseline level of wakefulness 
is higher, the percentage increase in wake was smaller. This 
is consistent with armodafinil in part working by decreasing 
the firing of VLPO neurons, which of course are already 
deactivated in VLPOx animals.Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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Figure 1 Histological assessment of VLPOx lesions, which produced a significant increase in wake and concomitant reduction in NREM and REM sleep. Representative 
photomicrographs of Nissl-stained brain sections from a (A) VLPOx rat and (B) a sham-L rat. (C) Daily percentages of sleep-wake stages (wake, NREM, REM) in sham-L 
(white bars) and VLPOx rats (black bars). Bilateral lesions of the VLPO produced a significant increase in wake and concomitant decreases in NREM and REM sleep.
Notes: Values are mean ± standard error of the mean; **P,0.01; scale bar: 500 µm.
Abbreviations: 3V, third ventricle; AC, anterior commissure; MPO, medial preoptic area; NREM, non-REM; OC, optic chiasm; REM, rapid eye movement; sham-L, sham-
lesioned; VLPO, ventrolateral preoptic area; VLPOx, VLPO-lesioned.
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Figure 2 The wake-promoting effects of armodafinil and methamphetamine are not attenuated in VLPOx rats compared to sham-L rats. Both (A) armodafinil and 
(B) methamphetamine produced a sustained increase in wake for approximately 3 hours in both VLPOx and sham-L rats. A persisting and significant increase in wake was 
observed into the (A) 5th hour post-injection hour and the (B) 6th post-injection hour in VLPOx rats compared to sham-L rats. Wake amounts during the 5th and 6th post-
injection hours did not differ between armodafinil and methamphetamine injected VLPOx rats and VLPOx rats receiving vehicle injections.
Notes: Data are mean ± standard error of the mean; **P,0.01 compared with VlPOx vehicle group; #P,0.01 when compared with either sham-L armodafinil or sham-L 
methamphetamine group.
Abbreviations: meth, methamphetamine; sham-L, sham-lesioned; VLPOx, ventrolateral preoptic area-lesioned.
c-Fos response to armodafinil  
or methamphetamine
In the present study we also observed marked behavioral 
differences in the animals following armodafinil versus 
methamphetamine administration. For example, whereas 
all of our armodafinil injected rats (VLPOx and Sham-L) 
showed clear behavioral arousal during the post-injection 
window the methamphetamine injected rats exhibited more 
active behaviors, including chewing of bedding and food and 
general hyperactivity during this same time. c-Fos analysis Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
Dovepress 
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was therefore performed on the brains of a naive cohort of 
rats (n=12) injected with either armodafinil (200 mg/kg) or 
methamphetamine (1 mg/kg). We observed almost no differ-
ences across the neuraxis in c-Fos expression between animals 
receiving armodafinil and those receiving methamphetamine. 
Comparable c-Fos expression was observed in the cortex 
(cingulate, insular), thalamic nuclei, basal forebrain, striatum 
(Figure 3), hypothalamus, amygdala, midbrain (eg, retro-VTA) 
and brainstem (eg, locus coeruleus) in animals receiving 
armodafinil versus methamphetamine. Our c-Fos findings in 
armodafinil injected rats are thus virtually identical to those 
reported by Scammell et al15 in modafinil injected rats.
Discussion
In light of its potent wake-promoting properties and routine 
clinical usage in treatment of a spectrum of sleep-wake dis-
orders, it is remarkable that both modafinil’s cellular basis 
of action as well as its neuronal targets remains unresolved. 
Although most previous studies on the mechanism of 
modafinil have used the racemic mixture, in this study we 
focused on armodafinil (the R-isomer), which is believed to 
be the active enantiomer, to eliminate any extraneous effects 
from esmodafinil (the S-isomer). While recent work has 
pointed to an important role for dopaminergic neurotrans-
mission, including the specific possibility of dopamine-
dependent adrenergic signaling in modafinil’s mechanism 
of action,5,8 the neuronal site(s) at which this occurs remains 
undetermined. As sleep-promoting VLPO neurons are inhib-
ited by dopamine via activation of alpha-2 adrenoceptors14 
and noradrenergic inhibition of VLPO neurons is potentiated 
by modafinil in vitro,13 we hypothesized that modafinil might 
promote wake through one or both of these mechanisms at 
the level of the VLPO neurons in vivo. The results of the 
present study indicate that animals with large VLPO lesions 
demonstrate increased wakefulness at baseline, and when 
treated with either amphetamine or armodafinil have a smaller 
increase in wake compared to intact animals, but reach the 
same level of total wakefulness. Thus, our results are con-
sistent with one of the effects of armodafinil and metham-
phetamine being to shut down the VLPO, but that both drugs 
must have additional effects that account for the increase in 
wakefulness beyond baseline in the VLPOx animals.
In early work investigating potential neuronal targets 
for modafinil, Engber et al18 showed an increase in c-Fos 
expression in several hypothalamic and limbic structures, 
including the central nucleus of the amygdala, following 
modafinil administration in rats. Lin et al19 also studied the 
pattern of c-Fos activation after modafinil administration, 
but in cats, and emphasized increased expression in the 
anterior hypothalamic area. A later study in rats,15 which 
utilized a more sensitive c-Fos antiserum, found a much 
more extensive pattern of c-Fos expression after modafinil 
administration, including many neurons in arousal-
  promoting cell groups (such as the tuberomammillary 
nucleus and orexin neurons in the lateral hypothalamus), 
but also in the striatum, including the caudate-putamen 
and nucleus accumbens. This group also reported a reduc-
tion in c-Fos in the VLPO. Because the VLPO acts to 
decrease wake and the putative action of modafinil in the 
VLPO would be inhibitory, a decrease in c-Fos labeling is 
consistent with modafinil-mediated suppression of VLPO 
neuronal activity.
In the present study we evaluated c-Fos expression across 
the neuraxis in response to armodafinil or methamphetamine 
administration with the working hypothesis that the different 
Figure 3 c-Fos expression in the dorsal striatum following armodafinil, metham-
phetamine, or saline injections. 
Notes: Intraperitoneal administration of (A) saline did not induce c-Fos expression 
in the striatum, whereas intraperitoneal administration of (B) armodafinil (200 mg/kg) 
or (C) methamphetamine (1 mg/kg) induced robust c-Fos expression in the striatum 
2 hours post-injection. Scale bar: 200 µm.Nature and Science of Sleep 2014:6 submit your manuscript | www.dovepress.com
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behavioral profiles we observed post-drug administration (ie, 
armodafinil versus methamphetamine) would be reflected in 
differential CNS c-Fos expression. This, in turn, would pos-
sibly reveal candidate CNS structure(s) beyond the VLPO 
that are critical for mediating armodafinil’s wake-promoting 
properties. We in fact observed virtually no differences in 
c-Fos expression across CNS nuclei between armodafinil 
and methamphetamine treated animals. While the c-Fos 
finding is difficult to reconcile with the markedly different 
behavioral profiles observed post-injection, it may simply 
reflect a limitation of the c-Fos technique, which may not 
stain all activated cell groups. Alternatively, the degree to 
which armodafinil and methamphetamine activate c-Fos 
stained cell groups may not be reflected in the counts due to 
a ceiling effect (ie, maximal c-Fos expression at a less than 
maximum level of physiological activity).
Similar, however, to Scammell et al,15 our c-Fos results 
did differ from a previous report in cats19 insofar as we found 
near equivalent c-Fos expression in the striatum following 
armodafinil or methamphetamine injections at the same 
dosages used in the EEG-based work in the present study 
(Figure 3). The activation of neurons in the striatum is not 
typical of untreated waking rats, but is almost certainly due 
to activation of D1 receptors which cause an increase in 
intracellular cyclic adenosine monophosphate (cAMP), one 
of the key drivers of c-Fos expression.20 On the other hand, 
D2 receptor-bearing striatal neurons would not be expected 
to show c-Fos in response to dopaminergic stimulation, as 
the D2 receptor causes a decrease in intracellular cAMP.21 
Nevertheless, despite showing no c-Fos, inhibition of the 
D2-receptive neurons would be consistent with increased 
wake as well, as activation of these neurons in the nucleus 
accumbens by the A2a adenosine receptor is thought to 
cause sleepiness, and blockade of the A2a receptor by caf-
feine to cause wakefulness.22 Thus, the c-Fos seen in the 
striatum after modafinil may actually be in the neurons that 
are selectively not related to its wake-promoting effect. 
Given the current view of the role of striatal dopaminer-
gic transmission in addictive behaviors,23 these findings 
raise the interesting question of why (ar)modafinil’s abuse 
potential and addictive properties are so much lower than 
that of methamphetamine,24,25 which is an important area 
of future research.
Other studies have employed a wide range of methodolo-
gies including chemical toxins, neural lesions, and genetically 
modified mice in an attempt to determine the CNS site(s) 
via which modafinil exerts its wake-promoting influence. 
Similar to the present study, however, most of these studies 
have yielded surprisingly limited insight. For example, it was 
reported that chemical ablation of noradrenergic forebrain 
projections from the locus coeruleus (LC), an aminergic 
nucleus implicated in sleep-wake regulation, did not block the 
wake-promoting effects of modafinil in vivo nor, in fact, was 
baseline sleep altered.8 Similarly, bilateral, electrolytic lesions 
in rats of the central nucleus of the amygdala, a limbic region 
strongly activated by modafinil, also failed to attenuate the 
waking response to modafinil administration nor, again, was 
baseline sleep altered.26 Modafinil also effectively increased 
wakefulness in orexin null mice.27 Interestingly, mice lacking 
the melanin-concentrating hormone (MCH) type I receptor 
are less sensitive to modafinil’s wake-promoting proper-
ties,28 whereas dopamine transporter (DAT) knockout mice 
are completely unresponsive to modafinil administration.5 
It was more recently shown that both D1 and D2 receptors 
are necessary for mediating the arousal effect of modafinil.29 
Given, however, the broad CNS distribution of MCH type I 
receptors, DAT, and D1/D2 receptors, ranging from cortical 
and limbic to striatal, hypothalamic and brainstem targets, 
our findings do not identify specific CNS targets of modafinil 
or amphetamine.
One clue may come from the recent studies showing 
that caffeine causes increased locomotor activity in mice by 
its action blocking A2a adenosine receptors in the nucleus 
accumbens (NAc).22 Caffeine is a psychostimulant with 
similar wake-promoting and fatigue-countering properties 
as modafinil. As the NAc also contains D1 and D2 recep-
tors, this basal ganglia structure may be a key target of 
modafinil. Recent work has suggested that this may indeed 
be the case.30
Conclusion
The results of the present study show that, while inhibition 
of VLPO neurons is potentially one of the mechanisms by 
which armodafinil and methamphetamine exert their wake-
promoting effects, these compounds also likely act directly 
on wake-promoting circuitry.
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